To further prove the relevance of RHAMM expression in NSCLC to clinical pathological stages, we used the Director's Challenge cohort with lung adenocarcinomas from caArray of National Cancer Institute for validation [29]. The gene discussed is HMMR; the disease is non-small cell lung carcinoma.